JAMA Oncology最新文献

{"title":"Methodological Concerns With Lung Cancer Screening Estimates.","authors":"Todd Burus,Caree R McAfee,Pamela C Hull","doi":"10.1001/jamaoncol.2025.2584","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2584","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"51 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"State-Level Public Awareness of HPV, HPV Vaccine, and Association With Cancer.","authors":"Ashvita Garg,Haluk Damgacioglu,Evan M Graboyes,Souvik Seal,Ashish A Deshmukh,Kalyani Sonawane","doi":"10.1001/jamaoncol.2025.2638","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2638","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"7 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sintilimab Plus Axitinib for Advanced Fumarate Hydratase-Deficient Renal Cell Carcinoma: A Phase 2 Nonrandomized Clinical Trial.","authors":"Xingming Zhang,Haoyang Liu,Jiayu Liang,Junjie Zhao,Yongquan Wang,Yuntian Chen,Deying Kang,Qian Chen,Yaowen Zhang,Xiaoxue Yin,Yuhao Zeng,Zilin Wang,Xinan Sheng,Xin Yao,Kan Gong,Xiaodong Liu,Zhibin Chen,Mingxing Qiu,Wei Chen,Zongping Wang,Guangheng Luo,Tingting Zhou,Nanshan Yang,Xiuyi Pan,Ling Nie,Mengni Zhang,Junru Chen,Jinge Zhao,Xu Hu,Lijing Xu,Bo Tang,Jindong Dai,Haolin Liu,Yuchao Ni,Rui Huang,Qiang Wei,Xiang Li,Qiying He,Jiyan Liu,Pengfei Shen,Ni Chen,Zhenhua Liu,Guangxi Sun,Jin Yao,Hao Zeng","doi":"10.1001/jamaoncol.2025.2497","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2497","url":null,"abstract":"ImportanceFumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a lethal kidney cancer that has limited therapeutic options.ObjectiveTo evaluate the efficacy and safety of sintilimab plus axitinib for treatment of advanced FH-deficient RCC.Design, Setting, and ParticipantsThis phase 2 multicenter, open-label, single-arm nonrandomized clinical trial enrolled patients with pathologically confirmed, treatment-naive, advanced FH-deficient RCC and an Eastern Cooperative Oncology Group Performance Status of 0 to 2 from July 1, 2021, to August 29, 2023, across 8 institutions in China. The data cutoff date was December 1, 2024.InterventionPatients received sintilimab, 200 mg, intravenously every 3 weeks, combined with axitinib, 5 mg, orally twice daily, until disease progression, intolerable toxic effects, or withdrawal of consent.Main Outcomes and MeasuresThe primary end points were objective response rate (ORR) via Response Evaluation Criteria in Solid Tumors, version 1.1, and progression-free survival (PFS). Secondary end points included safety, overall survival, disease control rate (proportion of patients with complete or partial response or stable disease for ≥6 months), duration of response, and exploratory genomic-associated outcomes.ResultsOf 52 patients screened for eligibility, 41 patients (median [range] age, 36 [18-75] years; 10 [24%] female) were enrolled. The median (range) duration of follow-up was 26.0 (0.7-41.6) months. Overall, ORR was 56% (23 patients; 95% CI, 40%-72%), with a median duration of response of not reached (NR; 95% CI, 23.3 months to NR). The disease control rate was 73% (30 patients). The median PFS was 19.8 months (95% CI, 10.9 months to NR). Patients with low somatic copy number alteration burden showed more favorable therapeutic outcomes. Thirteen patients (32%) experienced grade 3 or higher treatment-related adverse events, with the most frequent being hypertriglyceridemia in 3 (7%), rash in 2 (5%), and anemia in 2 (5%).Conclusions and RelevanceIn this nonrandomized clinical trial, the combination of sintilimab and axitinib demonstrated encouraging ORR and PFS with manageable safety profile in patients with FH-deficient RCC. This combination therapy warrants further validation in a randomized clinical trial.Trial RegistrationClinicalTrials.gov Identifier: NCT04387500.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"18 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Breakthrough From China in a Rare Form of Kidney Cancer.","authors":"Daniel J George,Michael R Harrison","doi":"10.1001/jamaoncol.2025.2419","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2419","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"13 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Childhood Cancer Survivorship Globally: A Systematic Review.","authors":"Melissa Martos,Nicholas George,Farina E Arreguín-González,Malek Baassiri,Alma E Benito-Reséndiz,Nickhill Bhakta,Neel S Bhatt,Natalie Bradford,Matthew J Ehrhardt,Drew Fajardo,Melissa M Hudson,Maria G Jiménez-Carbajal,Jason Lam Shang Leen,Glenn Mbah Afungchwi,Christian Mueller,Maria Olsson,Ishu Poudyal,Natalie Pritchett,Oscar Ramirez,Julie Ritter,Venkatraman Radhakrishnan,Krishna Sagar Sharma,Amela Sijecic,M Clarise Valencia,Alia Zaidi,Anel Van Zyl,Lisa M Force","doi":"10.1001/jamaoncol.2025.2506","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2506","url":null,"abstract":"ImportanceAs childhood cancer survival improves worldwide, supporting the growing survivor population, who are at increased risk of morbidity and mortality compared with the general population, is critical. No prior publications have summarized the landscape of childhood cancer survivorship research globally and encompassed high-income countries (HICs) and low-income and middle-income countries (LMICs).ObjectiveTo describe the global distribution of childhood cancer survivorship research, including country of origin and study focus, with a systematic review.Evidence ReviewThe Global Index Medicus, CAB Direct, Embase, and PubMed were searched for childhood cancer survivorship studies published between January 1, 1980, and September 1, 2021. Included studies had full texts available and measured multimorbidity or classic survivorship outcomes in children who received a diagnosis of cancer when younger than 20 years. Two reviewers separately screened studies for eligibility. Studies were categorized by World Bank income group and World Health Organization region. Survivorship domains were classified using an existing framework and included mental, physical, or psychosocial health, recurrences and new cancers, and health promotion. Basic quality metrics were assessed, including sample size, source, and uncertainty reporting. χ2 And Fisher tests were used to compare income groups and regions, linear regression for associations between publication year and income group or study domains, and the Mann-Whitney U test for sample size.FindingsA total of 1558 studies were included from 43 countries and territories, with HICs and the combined World Health Organization American and European regions disproportionately represented (1478 [95.2%] and 1436 [92.5%], respectively, of all cohort and cross-sectional studies [n = 1553]). The proportion of LMIC studies increased over time. Physical effects predominated among survivorship domains studied, particularly in LMICs compared with HICs. In HICs, cohort and cross-sectional sample sizes were larger (median, 276.5 [IQR, 80.0-1732.5] vs 87.0 [IQR, 50.0-130.0]) and more often drawn from the entire population or multiple rather than single institutions.Conclusions and RelevanceThis systematic review results suggest that the global compendium of childhood cancer survivorship data does not reflect the global population of survivors. Supporting survivorship research in diverse regions and areas of study is crucial to achieving equitable long-term outcomes globally.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"8 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850821","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.","authors":"Ciro Celsa,Gabriele Di Maria,Pasquale Lombardi,Antonio D'Alessio,Claudia A M Fulgenzi,Leonardo Brunetti,Giulia F Manfredi,Bernardo Stefanini,Alba Sparacino,Cristina Rigamonti,Mario Pirisi,Charles Latchford,Marco Vaccaro,Marco Enea,Calogero Cammà,Giuseppe Cabibbo,David James Pinato","doi":"10.1001/jamaoncol.2025.2470","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2470","url":null,"abstract":"ImportanceMultiple immunotherapy-based combinations and tyrosine kinase inhibitors are approved for first-line treatment of unresectable or advanced hepatocellular carcinoma (HCC). While overall survival remains the primary efficacy end point, health-related quality of life (HR-QoL) represents a crucial complementary outcome that has not been comprehensively compared across available treatments.ObjectiveTo compare the HR-QoL effects associated with different first-line treatments for unresectable or advanced HCC and to integrate treatment-induced survival benefit with impact on patients' HR-QoL.Data SourcesThe MEDLINE, CENTRAL, and Scopus databases were systematically searched for studies published from inception through November 2024. The search was supplemented with manual reviews of reference lists and abstracts from main oncology conferences from the past 5 years (2020-2024).Study SelectionPhase 3 randomized clinical trials comparing tyrosine kinase inhibitor monotherapy to immune checkpoint inhibitor-based therapies in first-line advanced HCC and reporting HR-QoL deterioration were included.Data Extraction and SynthesisStudy selection and data extraction were performed by 2 independent reviewers, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. The Cochrane Collaboration tool was used to assess risk of bias. A bayesian network meta-analysis was performed using sorafenib as the comparator.Main Outcomes and MeasuresTime to deterioration of HR-QoL domains were assessed using the European Organization for Research and Treatment of Cancer's Quality-of-Life Questionnaire Core 30 and HCC18. Treatment ranking was calculated using surface under the cumulative ranking (SUCRA) for HR-QoL items.ResultsSeven HR-QoL items from 9 randomized clinical trials enrolling 6425 patients met inclusion criteria. SUCRA calculations showed that atezolizumab plus bevacizumab had the highest probability of reducing deterioration of global health status and QoL (85%), abdominal swelling (95%), jaundice (89%), and pain (86%). When integrating HR-QoL with overall survival, atezolizumab plus bevacizumab outperformed all other treatments across all items.Conclusions and RelevanceThis network meta-analysis found that atezolizumab plus bevacizumab provides the best balance between QoL preservation and overall survival benefit compared to other systemic therapy options in unresectable or advanced HCC. This integrated assessment of survival and quality of life outcomes offers a more patient-centered approach for treatment selection in clinical practice.","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"4 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Methodological Concerns With Lung Cancer Screening Estimates-Reply.","authors":"LaShae D Rolle,Tracy E Crane","doi":"10.1001/jamaoncol.2025.2581","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2581","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"750 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144850827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inaccurate References in Systematic Review of Therapy for Advanced Non-Clear Cell Renal Cell Carcinoma.","authors":"Fausto Petrelli","doi":"10.1001/jamaoncol.2025.3550","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.3550","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"8 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812947","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Patient With Prior Skin Cancers and New Diagnosis of Bell Palsy.","authors":"Ramtin Rahmani,Hyunseok Kang,Jason W Chan","doi":"10.1001/jamaoncol.2025.2577","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2577","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"731 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144792038","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer Care Without a Safety Net-How Oncology Practices Confront the Gap.","authors":"Samyukta Mullangi,Richard L Martin","doi":"10.1001/jamaoncol.2025.2587","DOIUrl":"https://doi.org/10.1001/jamaoncol.2025.2587","url":null,"abstract":"","PeriodicalId":14850,"journal":{"name":"JAMA Oncology","volume":"27 1","pages":""},"PeriodicalIF":28.4,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144792037","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}